NCT07045298Not yet recruiting
CGM Use in Heart Failure
Real-Time Continuous Glucose Monitoring for the Management of Patients With Type 2 Diabetes and Acutely Decompensated Heart Failure
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually. More than 40% of hospitalized patients with HF have diabetes mellitus (DM), which increases the risk of recurrent hospitalizations for HF with reduced and preserved ejection fraction by more than two-fold. Current methods for assessing glycemic control do not consider fluctuations in blood glucose levels, known as glycemic variability. High glycemic variability is a poor prognostic marker for HF re-hospitalizations. Given the significant prevalence and impact of DM in individuals with HF, it is crucial to examine whether improving glycemic control and avoiding hypoglycemia could lead to a decrease in HF readmissions. Real-time continuous glucose monitoring (rt-CGM), which provides glucose measurements as frequently as every 5 minutes, has improved glycemic control in insulin-treated adults with DM compared to the standard of care, capillary point-of-care blood glucose testing (POC). Researchers will monitor participants during their hospital stay and 3 months after discharge.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 27 May 2025
- Start date
- Nov 2026
- Primary completion date
- Nov 2027
- Lead sponsor
- Emory University
- Diseases
- Heart failure, Type 2 diabetes
- NCT number
- NCT07045298
What you commit to
- Study type: Interventional
- Planned participants: 140
- From Nov 2026 to the primary completion date, Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of cardiac surgery (within 90 days before enrollment) or planned cardiac interventions within the following 6 months;
Other illness
- Patients with a history of type 1 diabetes;
- Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study;
- History of a heart transplant or listed for a heart transplant;
Age
- Age \< 18 or \> 90 years;
Other
- Patients on ventricular assist devices;
- Female participants who are pregnant or breastfeeding at the time of enrollment into the study;
- Hospice care or expected life expectancy of less than 6 months;
- Patients who are expected to require Magnetic Resonance Imaging (MRI) procedures during hospitalization or after discharge.
Who the study is looking for
- Adults 18 to 90 years admitted with a diagnosis of acute decompensated heart failure (ADHF), New York Heart Association (NYHA) class II, III, or IV symptoms (Aim 1) and discharged with a clinical diagnosis of ADHF (Aim 2).
- Patients with diabetes treated with diet alone or oral antidiabetic agents, Glucagon-like peptide-1 receptor agonists (GLP1-RAs), or insulin after discharge
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Grady Health System Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.